Trestle Biotherapeutics Analysis: $125K Raised
What is Trestle Biotherapeutics?
Trestle Biotherapeutics develops bioengineered therapies for kidney disease, focusing on implantable tissues to enhance patient outcomes and reduce dialysis dependence.
Product Features & Capabilities
- implantable therapeutic tissues for end-stage renal disease, bioengineered tissues to replace dialysis, potential to delay kidney transplantation, solutions for organ failure
How much Trestle Biotherapeutics raised
1 - $125K
2021Lead Investor: Y Combinator, Formic Ventures, and 1 other
Who are the founders of Trestle Biotherapeutics
BS
Ben Shepherd
Co-Founder, CEO
AC
Alice Chen
Co-Founder, Chief Scientific Officer
Competitors Overview
Trestle Biotherapeutics operates in the biotherapeutics market, focusing on bioengineered therapies for kidney disease, particularly through implantable therapeutic tissues. Its main competitors include:
- Amgen: A leading biotechnology company known for its innovative treatments across variou
Business Model
Focus on partnerships, grants, and funding for research and development revenue.
Market Focus
Trestle Biotherapeutics primarily focuses on the biopharmaceutical industry, specifically developing bioengineered therapies for kidney disease, including implantable therapeutic tissues for patients with end-stage renal disease (ESRD).
Investors
- KidneyX Innovation Accelerator
- Acequia Capital (AceCap)
- Y Combinator
- Formic Ventures
- Black Mountain Ventures
- C3 Ventures
- Axial VC
- Wellcome Leap HOPE Program
See something that needs updating? Suggest edits to this profile.